MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-12.50M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About MAIA

MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second- or later line of treatment for Non-Small Cell Lung Cancer (NSCLC) for patients that have progressed beyond the standar...

IndustryHealth Care
Founded2018
CEOVlad Vitoc
Employees9
Stock ExchangeNASDAQ
Ticker SymbolMAIA
Full Company Profile

Financial Performance

Financial Statements

News

Cancer biotech MAIA Biotechnology files for a $15 million IPO

MAIA Biotechnology, a Phase 2 biotech developing targeted immunotherapies for cancer, filed on Monday with the SEC to raise up to $15 million in an initial public offering.

1 month ago - Renaissance Capital

MAIA Biotechnology IPO Registration Document (S-1)

MAIA Biotechnology has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC